These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
522 related articles for article (PubMed ID: 32425941)
21. Reduced binding of apoE4 to complement factor H promotes amyloid-β oligomerization and neuroinflammation. Chernyaeva L; Ratti G; Teirilä L; Fudo S; Rankka U; Pelkonen A; Korhonen P; Leskinen K; Keskitalo S; Salokas K; Gkolfinopoulou C; Crompton KE; Javanainen M; Happonen L; Varjosalo M; Malm T; Leinonen V; Chroni A; Saavalainen P; Meri S; Kajander T; Wollman AJ; Nissilä E; Haapasalo K EMBO Rep; 2023 Jul; 24(7):e56467. PubMed ID: 37155564 [TBL] [Abstract][Full Text] [Related]
22. Apolipoprotein E Isoforms Differentially Regulate Alzheimer's Disease and Amyloid-β-Induced Inflammatory Response in vivo and in vitro. Dorey E; Bamji-Mirza M; Najem D; Li Y; Liu H; Callaghan D; Walker D; Lue LF; Stanimirovic D; Zhang W J Alzheimers Dis; 2017; 57(4):1265-1279. PubMed ID: 28372324 [TBL] [Abstract][Full Text] [Related]
23. Apolipoprotein E and Alzheimer's Disease: Findings, Hypotheses, and Potential Mechanisms. Koutsodendris N; Nelson MR; Rao A; Huang Y Annu Rev Pathol; 2022 Jan; 17():73-99. PubMed ID: 34460318 [TBL] [Abstract][Full Text] [Related]
24. Apolipoprotein E isoforms differentially regulate matrix metallopeptidase 9 function in Alzheimer's disease. Ringland C; Schweig JE; Paris D; Shackleton B; Lynch CE; Eisenbaum M; Mullan M; Crawford F; Abdullah L; Bachmeier C Neurobiol Aging; 2020 Nov; 95():56-68. PubMed ID: 32758917 [TBL] [Abstract][Full Text] [Related]
25. Apolipoprotein E and oxidative stress in brain with relevance to Alzheimer's disease. Butterfield DA; Mattson MP Neurobiol Dis; 2020 May; 138():104795. PubMed ID: 32036033 [TBL] [Abstract][Full Text] [Related]
26. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. Fryer JD; Simmons K; Parsadanian M; Bales KR; Paul SM; Sullivan PM; Holtzman DM J Neurosci; 2005 Mar; 25(11):2803-10. PubMed ID: 15772340 [TBL] [Abstract][Full Text] [Related]
27. APOE4 is a Risk Factor and Potential Therapeutic Target for Alzheimer's Disease. Ayyubova G CNS Neurol Disord Drug Targets; 2024; 23(3):342-352. PubMed ID: 36872358 [TBL] [Abstract][Full Text] [Related]
28. Apoe4 and Alzheimer's Disease Pathogenesis-Mitochondrial Deregulation and Targeted Therapeutic Strategies. Pires M; Rego AC Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614219 [No Abstract] [Full Text] [Related]
29. Levels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. Tai LM; Bilousova T; Jungbauer L; Roeske SK; Youmans KL; Yu C; Poon WW; Cornwell LB; Miller CA; Vinters HV; Van Eldik LJ; Fardo DW; Estus S; Bu G; Gylys KH; Ladu MJ J Biol Chem; 2013 Feb; 288(8):5914-26. PubMed ID: 23293020 [TBL] [Abstract][Full Text] [Related]
30. Apolipoprotein E level and cholesterol are associated with reduced synaptic amyloid beta in Alzheimer's disease and apoE TR mouse cortex. Arold S; Sullivan P; Bilousova T; Teng E; Miller CA; Poon WW; Vinters HV; Cornwell LB; Saing T; Cole GM; Gylys KH Acta Neuropathol; 2012 Jan; 123(1):39-52. PubMed ID: 22020632 [TBL] [Abstract][Full Text] [Related]
31. Characterization of the binding of amyloid-beta peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma. Yang DS; Smith JD; Zhou Z; Gandy SE; Martins RN J Neurochem; 1997 Feb; 68(2):721-5. PubMed ID: 9003062 [TBL] [Abstract][Full Text] [Related]
32. Understanding the Role of ApoE Fragments in Alzheimer's Disease. Muñoz SS; Garner B; Ooi L Neurochem Res; 2019 Jun; 44(6):1297-1305. PubMed ID: 30225748 [TBL] [Abstract][Full Text] [Related]
33. Isoform-Specific Effects of Apolipoprotein E on Markers of Inflammation and Toxicity in Brain Glia and Neuronal Cells In Vitro. Iannucci J; Sen A; Grammas P Curr Issues Mol Biol; 2021 May; 43(1):215-225. PubMed ID: 34071762 [TBL] [Abstract][Full Text] [Related]
34. ApoE4-mediated blood-brain barrier damage in Alzheimer's disease: Progress and prospects. Zhou X; Shi Q; Zhang X; Gu L; Li J; Quan S; Zhao X; Li Q Brain Res Bull; 2023 Jul; 199():110670. PubMed ID: 37224887 [TBL] [Abstract][Full Text] [Related]
35. Neuronal ApoE4 in Alzheimer's disease and potential therapeutic targets. Zhang L; Xia Y; Gui Y Front Aging Neurosci; 2023; 15():1199434. PubMed ID: 37333457 [TBL] [Abstract][Full Text] [Related]
36. The pathological cross talk between apolipoprotein E and amyloid-beta peptide in Alzheimer's disease: emerging gene-based therapeutic approaches. Iurescia S; Fioretti D; Mangialasche F; Rinaldi M J Alzheimers Dis; 2010; 21(1):35-48. PubMed ID: 20182014 [TBL] [Abstract][Full Text] [Related]
37. Apolipoprotein E isoforms in Alzheimer's disease pathology and etiology. Baum L; Chen L; Ng HK; Pang CP Microsc Res Tech; 2000 Aug; 50(4):278-81. PubMed ID: 10936880 [TBL] [Abstract][Full Text] [Related]
39. Blocking the apolipoprotein E/amyloid β interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid β and tau pathology. Liu S; Breitbart A; Sun Y; Mehta PD; Boutajangout A; Scholtzova H; Wisniewski T J Neurochem; 2014 Feb; 128(4):577-91. PubMed ID: 24117759 [TBL] [Abstract][Full Text] [Related]
40. Effect of apolipoprotein AII on the interaction of apolipoprotein E with beta-amyloid: some apo(E-AII) complexes inhibit the internalization of beta-amyloid in cultures of neuroblastoma cells. Yamauchi K; Tozuka M; Hidaka H; Nakabayashi T; Sugano M; Kondo Y; Nakagawara A; Katsuyama T J Neurosci Res; 2000 Nov; 62(4):608-14. PubMed ID: 11070505 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]